Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/2638
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBrito-Zerón, Pilar-
dc.contributor.authorKostov, Belchin-
dc.contributor.authorFraile, Guadalupe-
dc.contributor.authorCaravia-Durán, Daniel-
dc.contributor.authorMaure, Brenda-
dc.contributor.authorRascón, Francisco-Javier-
dc.contributor.authorZamora, Mónica-
dc.contributor.authorCasanovas, Arnau-
dc.contributor.authorLopez-Dupla, Miguel-
dc.contributor.authorRipoll, Mar-
dc.contributor.authorPinilla, Blanca-
dc.contributor.authorFonseca, Eva-
dc.contributor.authorAkasbi, Miriam-
dc.contributor.authorde la Red, Gloria-
dc.contributor.authorDuarte-Millán, Miguel-Angel-
dc.contributor.authorFanlo, Patricia-
dc.contributor.authorGuisado-Vasco, Pablo-
dc.contributor.authorPérez-Alvarez, Roberto-
dc.contributor.authorChamorro, Antonio J-
dc.contributor.authorMorcillo, César-
dc.contributor.authorJiménez-Heredia, Iratxe-
dc.contributor.authorSánchez-Berná, Isabel-
dc.contributor.authorLópez-Guillermo, Armando-
dc.contributor.authorRamos-Casals, Manuel-
dc.date.accessioned2017-05-08T09:41:41Z-
dc.date.available2017-05-08T09:41:41Z-
dc.date.issued2017-04-17-
dc.identifier.citationBrito-Zerón P, Kostov B, Fraile G, Caravia-Durán D, Maure B, Rascón FJ et al. Characterization and risk estimate of cancer in patients with primary Sjögren syndrome. J Hematol Oncol. 2017 Apr 17;10(1):90.es_ES
dc.identifier.issn1756-8722 (Online)es_ES
dc.identifier.otherPMC5392920es_ES
dc.identifier.urihttp://hdl.handle.net/10668/2638-
dc.descriptionThe members of the SS Study Group, Autoimmune Diseases Study Group (GEAS), Spanish Society of Internal Medicine (SEMI) involved in this project have been: M. Ramos-Casals (Coordinator), P. Brito-Zerón, S. Retamozo, A. Bové, H. Gheitasi,I. Sánchez-Berná, J. Gratacós (Sjögren Syndrome Research Group-AGAUR, Laboratory of Autoimmune Diseases Josep Font, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Autoimmune Diseases, ICMiD, Hospital Clínic, Barcelona); G. Fraile, J. Nava-Mateos (Department of Internal Medicine, Hospital Ramón y Cajal, Madrid); B.Díaz-López, D. Caravia-Duran, A. García-Pérez (Department of Internal Medicine, Hospital Universitario Central de Asturias, Oviedo); A.Casanovas, M.L. Morera-Morales, T.E. Junco-Russeau (Department of Internal Medicine, Hospital Parc Taulí, Sabadell); F.J. Rascón, L. Pallarés (Department of Internal Medicine, Hospital Son Espases, Palma de Mallorca); R. Pérez-Alvarez, M. Perez-de-Lis (Department of Internal Medicine, Hospital Alvaro Cunqueiro); M. Ripoll, C. Moreno-delaSantaGarcía (Department of Internal Medicine, Hospital Infanta Sofía, Madrid); B. Pinilla, C. López-GónzalezCobos (Department of Internal Medicine, Hospital Gregorio Marañón, Madrid); M. Akasbi, I. García-Sanchez (Department of Internal Medicine, Hospital Infanta Leonor, Madrid); B.Maure (Department of Internal Medicine, Complejo Hospitalario Universitario, Vigo); E. Fonseca (Department of Internal Medicine, Hospital de Cabueñes, Gijón); M.A. Duarte-Millán, J. Canora (Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid); G de la Red, N. Msabri (Department of Internal Medicine, Hospital Esperit Sant, Santa Coloma de Gramenet, Barcelona); A.J. Chamorro, S. Rodríguez Rodríguez (Department of Internal Medicine, Complejo Hospitalario de Salamanca, Salamanca); I. Jiménez-Heredia (Department of Internal Medicine, Hospital de Sagunt, Valencia, Spain); M.A. López-Dupla, J.A.Porras-Ledantes, B. Villar-Navas, J. Ramos-Rodriguez (Department of Internal Medicine, Hospital Joan XXIII, Tarragona); P. Brito-Zerón, C. Morcillo (Department of Internal Medicine, Hospital CIMA-Sanitas, Barcelona); M. Zamora, I. Sánchez-Berná (Department of Internal Medicine, Hospital Virgen de las Nieves, Granada); P. Fanlo (Department of Internal Medicine, Hospital Virgen del Camino, Pamplona); P. Guisado-Vasco (Department of Internal Medicine, Complejo Hospitalario Ruber Juan Bravo, Madrid); B. Kostov, A. Sisó-Almirall (Primary Care Research Group, IDIBAPS, Centre d’Assistència Primària ABS Les Corts, CAPSE, Barcelona, Spain).es_ES
dc.description.abstractBACKGROUND: The purpose of this study is to characterize the risk of cancer in a large cohort of patients with primary Sjögren syndrome (SjS). METHODS: We had analyzed the development of cancer in 1300 consecutive patients fulfilling the 2002 SjS classification criteria. The baseline clinical and immunological characteristics and systemic activity (ESSDAI scores) were assessed at diagnosis as predictors of cancer using Cox proportional hazards regression analysis adjusted for age at diagnosis and gender. The sex-and age-specific standardized incidence ratios (SIR) of cancer were estimated from 2012 Spanish mortality data. RESULTS: After a mean follow-up of 91 months, 127 (9.8%) patients developed 133 cancers. The most frequent type of cancer was B-cell lymphoma (including 27 MALT and 19 non-MALT B-cell lymphomas). Systemic activity at diagnosis of primary SjS correlated with the risk of hematological neoplasia and cryoglobulins with a high risk of either B-cell or non-B-cell lymphoma subtypes. Patients with cytopenias had a high risk of non-MALT B-cell and non-B-cell cancer, while those with low C3 levels had a high risk of MALT lymphomas and those with monoclonal gammopathy and low C4 levels had a high risk of non-MALT lymphomas. The estimated SIR for solid cancer was 1.13 and 11.02 for hematological cancer. SIRs for specific cancers were 36.17 for multiple myeloma and immunoproliferative diseases, 19.41 for Hodgkin lymphoma, 6.04 for other non-Hodgkin lymphomas, 5.17 for thyroid cancer, 4.81 for cancers of the lip and oral cavity, and 2.53 for stomach cancer. CONCLUSIONS: One third of cancers developed by patients with primary SjS are B-cell lymphomas. The prognostic factors identified at SjS diagnosis differed according to the subtype of B-cell lymphoma developed. Primary SjS is also associated with the development of some non-hematological cancers (thyroid, oral cavity, and stomach).es_ES
dc.description.sponsorshipThis work is supported by the Grant Fondo de Investigaciones Sanitarias (MRC, INT15/00085) and by the “CERCA Programme/Generalitat de Catalunya”.es_ES
dc.language.isoenes_ES
dc.publisherBioMed Centrales_ES
dc.relation.ispartofJournal of Hematology & Oncologyes_ES
dc.subjectSjögren syndromees_ES
dc.subjectCanceres_ES
dc.subjectLymphomaes_ES
dc.subjectCrioglobulinases_ES
dc.subjectEstudios de seguimientoes_ES
dc.subjectEnfermedad de hodgkines_ES
dc.subjectIncidenciaes_ES
dc.subjectLabioes_ES
dc.subjectLinfoma de células b de la zona marginales_ES
dc.subjectGammopatía monoclonal de relevancia indeterminadaes_ES
dc.subjectMieloma múltiplees_ES
dc.subjectPronósticoes_ES
dc.subjectAnálisis de regresiónes_ES
dc.subjectSíndrome de sjögrenes_ES
dc.subjectNeoplasias gástricases_ES
dc.subjectNeoplasias de la tiroideses_ES
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Globulins::Serum Globulins::Immunoglobulins::Paraproteins::Cryoglobulinses_ES
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Follow-Up Studieses_ES
dc.subject.meshMedical Subject Headings::Diseases::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Hodgkin Diseasees_ES
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Incidencees_ES
dc.subject.meshMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humanses_ES
dc.subject.meshMedical Subject Headings::Anatomy::Stomatognathic System::Mouth::Lipes_ES
dc.subject.meshMedical Subject Headings::Diseases::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, B-Cell, Marginal Zonees_ES
dc.subject.meshMedical Subject Headings::Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Blood Protein Disorders::Hypergammaglobulinemia::Monoclonal Gammopathy of Undetermined Significancees_ES
dc.subject.meshMedical Subject Headings::Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Plasma Cell::Multiple Myelomaes_ES
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosises_ES
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Regression Analysises_ES
dc.subject.meshMedical Subject Headings::Diseases::Immune System Diseases::Autoimmune Diseases::Arthritis, Rheumatoid::Sjogren's Syndromees_ES
dc.subject.meshMedical Subject Headings::Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Stomach Neoplasmses_ES
dc.subject.meshMedical Subject Headings::Diseases::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Thyroid Neoplasmses_ES
dc.titleCharacterization and risk estimate of cancer in patients with primary Sjögren syndromees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.versionYeses_ES
dc.contributor.groupThe SS Study Group GEAS-SEMIes_ES
dc.identifier.pmid28416003es_ES
dc.rights.accessRightsAcceso abiertoes_ES
dc.identifier.doi10.1186/s13045-017-0464-5es_ES
dc.type.versioninfo:eu-repo/semantics/publishedes_ES
dc.relation.publisherversionhttps://jhoonline.biomedcentral.com/articles/10.1186/s13045-017-0464-5#Abs1es_ES
dc.contributor.authoraffiliation[Morcillo,C; Brito-Zerón,P] Autoimmune Diseases Unit, Department of Internal Medicine, Hospital CIMA-Sanitas, Barcelona, Spain. [Brito-Zerón;P: Sánchez-Berná,I; Ramos-Casals,M] Laboratory of Autoimmune Diseases Josep Font, IDIBAPS, Department of Autoimmune Diseases, ICMiD, Hospital Clínic, Barcelona, Spain. [Kostov,B] Transversal group for research in primary care, IDIBAPS, Consorci d’Atenció Primària de Salut Barcelona Esquerre (CAPSBE), Barcelona, Spain. [Fraile,G] Department of Internal Medicine, Hospital Ramón y Cajal, Madrid, Spain. [Caravia-Durán,D] Department of Internal Medicine, Hospital Universitario Central de Asturias, Oviedo, Spain. [Maure,B] Department of Internal Medicine, Complejo Hospitalario Universitario, Vigo, Spain. [Rascón,FJ] Department of Internal Medicine, Hospital Son Espases, Palma de Mallorca, Spain. [Zamora,M; Sánchez-Berná,I] Department of Internal Medicine, Hospital Virgen de las Nieves, Granada, Spain. [Casanovas,A] Department of Internal Medicine, Hospital Parc Taulí, Sabadell, Spain. [ Lopez-Dupla,M] Department of Internal Medicine, Hospital Joan XXIII, Tarragona, Spain. [Ripoll,M] Department of Internal Medicine, Hospital Infanta Sofía, Madrid, Spain. [Pinilla,B] Department of Internal Medicine, Hospital Gregorio Marañón, Madrid, Spain. [Fonseca,E] Department of Internal Medicine, Hospital de Cabueñes, Gijón, Spain. [Akasbi,M] Department of Internal Medicine, Hospital Infanta Leonor, Madrid, Spain. [de la Red,G] Department of Internal Medicine, Hospital Esperit Sant, Santa Coloma de Gramenet, Spain. [Duarte-Millán,MA] Department of Internal Medicine, Hospital de Fuenlabrada, Fuenlabrada, Spain. [Fanlo,P] Department of Internal Medicine, Hospital Virgen del Camino, Pamplona, Spain. [Guisado-Vasco,P] Department of Internal Medicine, Complejo Hospitalario Ruber Juan Bravo, Madrid, Spain. [Pérez-Alvarez,R] Department of Internal Medicine, Hospital Alvaro Cunqueiro, Vigo, Spain. [Chamorro,AJ] Department of Internal Medicine, Hospital de Salamanca, Salamanca, Spain. [ Jiménez-Heredia,i] Department of Internal Medicine, Hospital de Sagunto, Valencia, Spain. [López-Guillermo,A] Department of Hematology, ICMHO, Hospital Clinic, Barcelona, Spain. [Ramos-Casals,M] Department of Medicine, University of Barcelona, Barcelona, Spain.es_ES
Appears in Collections:01- Artículos - Complejo Hospitalario Universitario de Granada

Files in This Item:
File Description SizeFormat 
BritoZeron_CharacterizationAndRiskEstimate.pdfArtículo publicado450,42 kBAdobe PDFView/Open
BritoZeron_CharacterizationAndRiskEstimateFile1.odtMaterial suplementario19,35 kBOpenDocument TextView/Open
BritoZeronCharacterizationAndRiskEstimateFile2.tifMaterial suplementario187,52 kBTIFFView/Open


This item is protected by original copyright



This item is licensed under a Creative Commons License Creative Commons